Wafergen Bio-Systems (WGBS) 4.50 $WGBS
WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million
PR Newswire - Wed Aug 27, 2:15PM CDT
WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it has completed its previously announced underwritten public offering of units of common stock and warrants at a price of $10,000 per unit for gross proceeds of $20 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The shares and warrants are immediately separable and will be issued separately.
WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ
PR Newswire - Fri Aug 22, 7:00AM CDT
WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the pricing of an underwritten public offering of units of common stock and warrants at a price of $10,000 per unit for gross proceeds of $20 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The shares and warrants are immediately separable and will be issued separately. The shares of common stock are expected to begin trading on The NASDAQ Stock Market under the ticker symbol "WGBS" on Friday, August 22, 2014. The offering is expected to close on August 27, 2014, subject to the satisfaction or waiver of customary closing conditions.
WaferGen Announces Appointment of Chief Operating Officer and Chief Financial Officer
PR Newswire - Mon Aug 18, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) today announced that the Company has appointed two seasoned executives to its senior management team, Keith Warner as Chief Operating Officer and Michael Henighan as Chief Financial Officer.
WaferGen Bio-systems Reports Strong Revenue Growth for Q2 2014
PR Newswire - Thu Aug 07, 3:01PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the second quarter ended June 30, 2014.
WaferGen Bio-systems Announces Second Quarter 2014 Conference Call
PR Newswire - Mon Aug 04, 3:01PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today that it will host a conference call to discuss its financial results for the quarter ended June 30, 2014. The call will be held on Thursday, August 7, 2014 at 5:00 pm ET and will be hosted by Ivan Trifunovich, President and CEO of WaferGen Bio-systems.
WaferGen Bio-systems Announces a Commercial Partnership with a Major Molecular Diagnostic Laboratory
PR Newswire - Thu Jul 31, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today a commercial partnership with Molecular Pathology Laboratory Network, Inc. (MPLN) with the goal of developing Next-Generation sequencing (NGS) based clinical tests.
WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director
PR Newswire - Fri Jul 18, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBSD) today announced that its Board of Directors has appointed Ivan Trifunovich, the company's President and Chief Executive Officer, as Chairman of the Board. Joel Kanter, a director of the company since 2007, will serve as lead independent director. Alnoor Shivji, the company's Chairman since 2002, resigned from the board to focus full time on a new startup venture.
WaferGen Bio-systems Announces Reverse Stock Split as it Pursues NASDAQ Listing
PR Newswire - Mon Jun 30, 3:02PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a 1-for-10 reverse stock split of its outstanding common stock. The company completed the reverse stock split as it seeks to list its common stock on the NASDAQ Capital Market.
WaferGen Bio-systems Announces Fourth Quarter and Year-End 2013 Conference Call
PR Newswire - Tue Mar 18, 5:12PM CDT
WaferGen Bio-systems, Inc. (WGBS) announced today that it will host a conference call and live audio webcast to discuss its financial results for the quarter and year ended December 31, 2013. The call and webcast will be held on Monday, March 24, 2014 at 11:00 am ET and will be hosted by Ivan Trifunovich, President and CEO of WaferGen Bio-systems.
WaferGen Bio-systems Reports Solid Revenue Growth for Q4 and the Year 2013
PR Newswire - Thu Mar 13, 4:42PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the fourth quarter and year ended December 31, 2013.
Hepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies, and Forecasts Report Available Online By ResearchMoz.us
PR Newswire - Wed Feb 19, 5:31AM CST
ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports.
Anvil Rock Ventures LLC Introduces FirstFrontiersMan.com
PR Newswire - Tue Jan 28, 8:24AM CST
Arizona-based internet company, Anvil Rock Ventures LLC, today announced that its new online store is open for business at www.FirstFrontiersMan.com.
WaferGen Bio-systems Acquires a Leading Next-Generation Sequencing (NGS) Library Preparation Business and Announces Changes to its Board of Directors
PR Newswire - Tue Jan 07, 8:10AM CST
WaferGen Bio-systems, Inc. (QTCQB: WGBS) announced today the acquisition of the NGS library preparation business from IntegenX Inc. Pursuant to the asset purchase agreement, WaferGen Bio-systems, Inc., through Wafergen, Inc., its wholly owned subsidiary, acquired on January 6, 2014 substantially all of the assets of IntegenX's product line used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for NGS, including the Apollo 324TM instrument and PrepX® reagents. The purchase price for the acquired business was composed of (1) an up-front cash payment of $2.0 million, (2) a $1.25 million secured promissory note due on January 6, 2017 (repayable early in certain circumstances), (3) up to three earn-out payments payable based on certain revenue thresholds in 2014, 2015 and 2016, respectively, and (4) Wafergen, Inc.'s assumption of certain liabilities related to the acquired business. Additional information on the transaction can be found in WaferGen's Report on Form 8-K filed with the SEC on January 6, 2014.
WaferGen Bio-systems Announces New Funding from Private Placement
PR Newswire - Tue Aug 27, 7:40PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today that it has commenced a private placement to accredited investors of up to $17.25 million of units consisting of shares of common stock, shares of Series 1 convertible preferred stock and warrants to purchase shares of common stock.
WaferGen Bio-systems Announces Reverse Stock Split and Capital Restructuring
PR Newswire - Tue Aug 27, 7:38PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a 1-for-99.39 reverse stock split of its outstanding common stock and the completion of a capital restructuring of its Series A-1 Convertible Preferred Stock, convertible promissory notes and warrants issued in May 2011. The Company completed the reverse stock split and capital restructuring as part of its efforts to improve its capital structure and raise additional capital.
WaferGen Launches SmartChip TE - A Novel Target Enrichment Solution for Next-Gen Sequencing (NGS) Aimed at Clinical Applications
PR Newswire - Thu May 09, 10:04AM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the launch of its new SmartChip TE product - a PCR-based target enrichment solution for sample preparation prior to targeted re-sequencing on Next-Gen platforms. As clinical Next-Gen sequencing rapidly expands into the mainstream molecular testing market, the growth of this market segment is expected to be explosive. Some analysts project that the market for targeted clinical sequencing alone will reach $750M by 2015. SmartChip TE addresses CLIA-certified and clinical research laboratories' significant unmet needs in sequencing-based testing by providing superior flexibility, specificity, and sensitivity. The superior performance of this new product is based on WaferGen's proprietary technology that relies on massively parallel singleplex PCR reactions, where amplification is cleaner and better controlled, thereby providing more accurate results in the downstream sequencing step. Each target is amplified in an individual reaction, yielding close to eq
WaferGen Partners with Salk Institute to Establish a Nano-qPCR Core Lab
PR Newswire - Mon Mar 11, 8:10AM CDT
The Salk Institute and WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the formation of a nano-qPCR Core Laboratory under the guidance of Ronald M. Evans, Professor and March of Dimes Chair in Molecular and Developmental Biology at Salk. The lab will utilize WaferGen's SmartChip System as the backbone technology for high-throughput real-time PCR studies. A major focus will be on designing and testing libraries of assays targeting receptors and transcriptional regulators for important functional pathways, thereby interrogating entire regulatory networks in a highly parallel fashion. It is also envisioned that the nano-qPCR Core Lab will be an important resource for the larger Salk community.
WaferGen Bio-systems Announces Highly Successful Initial Customer Testing of Its Previously Unannounced Novel Target Enrichment Technology for Next-Gen Sequencing (NGS)
PR Newswire - Tue Jan 08, 8:00AM CST
WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the successful completion of a proof-of-concept study using its newly-developed proprietary nano-qPCR technology for sample preparation prior to targeted re-sequencing on Next-Gen platforms. The results can be viewed in white paper form at:
WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million
PR Newswire - Wed Aug 27, 2:15PM CDT
WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it has completed its previously announced underwritten public offering of units of common stock and warrants at a price of $10,000 per unit for gross proceeds of $20 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The shares and warrants are immediately separable and will be issued separately.
WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ
PR Newswire - Fri Aug 22, 7:00AM CDT
WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the pricing of an underwritten public offering of units of common stock and warrants at a price of $10,000 per unit for gross proceeds of $20 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The shares and warrants are immediately separable and will be issued separately. The shares of common stock are expected to begin trading on The NASDAQ Stock Market under the ticker symbol "WGBS" on Friday, August 22, 2014. The offering is expected to close on August 27, 2014, subject to the satisfaction or waiver of customary closing conditions.
WaferGen Announces Appointment of Chief Operating Officer and Chief Financial Officer
PR Newswire - Mon Aug 18, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) today announced that the Company has appointed two seasoned executives to its senior management team, Keith Warner as Chief Operating Officer and Michael Henighan as Chief Financial Officer.
WaferGen Bio-systems Reports Strong Revenue Growth for Q2 2014
PR Newswire - Thu Aug 07, 3:01PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the second quarter ended June 30, 2014.
WaferGen Bio-systems Announces Second Quarter 2014 Conference Call
PR Newswire - Mon Aug 04, 3:01PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today that it will host a conference call to discuss its financial results for the quarter ended June 30, 2014. The call will be held on Thursday, August 7, 2014 at 5:00 pm ET and will be hosted by Ivan Trifunovich, President and CEO of WaferGen Bio-systems.
WaferGen Bio-systems Announces a Commercial Partnership with a Major Molecular Diagnostic Laboratory
PR Newswire - Thu Jul 31, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today a commercial partnership with Molecular Pathology Laboratory Network, Inc. (MPLN) with the goal of developing Next-Generation sequencing (NGS) based clinical tests.
WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director
PR Newswire - Fri Jul 18, 8:01AM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBSD) today announced that its Board of Directors has appointed Ivan Trifunovich, the company's President and Chief Executive Officer, as Chairman of the Board. Joel Kanter, a director of the company since 2007, will serve as lead independent director. Alnoor Shivji, the company's Chairman since 2002, resigned from the board to focus full time on a new startup venture.
WaferGen Bio-systems Announces Reverse Stock Split as it Pursues NASDAQ Listing
PR Newswire - Mon Jun 30, 3:02PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a 1-for-10 reverse stock split of its outstanding common stock. The company completed the reverse stock split as it seeks to list its common stock on the NASDAQ Capital Market.
WaferGen Bio-systems Announces Fourth Quarter and Year-End 2013 Conference Call
PR Newswire - Tue Mar 18, 5:12PM CDT
WaferGen Bio-systems, Inc. (WGBS) announced today that it will host a conference call and live audio webcast to discuss its financial results for the quarter and year ended December 31, 2013. The call and webcast will be held on Monday, March 24, 2014 at 11:00 am ET and will be hosted by Ivan Trifunovich, President and CEO of WaferGen Bio-systems.
WaferGen Bio-systems Reports Solid Revenue Growth for Q4 and the Year 2013
PR Newswire - Thu Mar 13, 4:42PM CDT
WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the fourth quarter and year ended December 31, 2013.
Hepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies, and Forecasts Report Available Online By ResearchMoz.us
PR Newswire - Wed Feb 19, 5:31AM CST
ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports.
Anvil Rock Ventures LLC Introduces FirstFrontiersMan.com
PR Newswire - Tue Jan 28, 8:24AM CST
Arizona-based internet company, Anvil Rock Ventures LLC, today announced that its new online store is open for business at www.FirstFrontiersMan.com.
WaferGen Bio-systems Acquires a Leading Next-Generation Sequencing (NGS) Library Preparation Business and Announces Changes to its Board of Directors
PR Newswire - Tue Jan 07, 8:10AM CST
WaferGen Bio-systems, Inc. (QTCQB: WGBS) announced today the acquisition of the NGS library preparation business from IntegenX Inc. Pursuant to the asset purchase agreement, WaferGen Bio-systems, Inc., through Wafergen, Inc., its wholly owned subsidiary, acquired on January 6, 2014 substantially all of the assets of IntegenX's product line used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for NGS, including the Apollo 324TM instrument and PrepX® reagents. The purchase price for the acquired business was composed of (1) an up-front cash payment of $2.0 million, (2) a $1.25 million secured promissory note due on January 6, 2017 (repayable early in certain circumstances), (3) up to three earn-out payments payable based on certain revenue thresholds in 2014, 2015 and 2016, respectively, and (4) Wafergen, Inc.'s assumption of certain liabilities related to the acquired business. Additional information on the transaction can be found in WaferGen's Report on Form 8-K filed with the SEC on January 6, 2014.
WaferGen Bio-systems Announces New Funding from Private Placement
PR Newswire - Tue Aug 27, 7:40PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today that it has commenced a private placement to accredited investors of up to $17.25 million of units consisting of shares of common stock, shares of Series 1 convertible preferred stock and warrants to purchase shares of common stock.
WaferGen Bio-systems Announces Reverse Stock Split and Capital Restructuring
PR Newswire - Tue Aug 27, 7:38PM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a 1-for-99.39 reverse stock split of its outstanding common stock and the completion of a capital restructuring of its Series A-1 Convertible Preferred Stock, convertible promissory notes and warrants issued in May 2011. The Company completed the reverse stock split and capital restructuring as part of its efforts to improve its capital structure and raise additional capital.
WaferGen Launches SmartChip TE - A Novel Target Enrichment Solution for Next-Gen Sequencing (NGS) Aimed at Clinical Applications
PR Newswire - Thu May 09, 10:04AM CDT
WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the launch of its new SmartChip TE product - a PCR-based target enrichment solution for sample preparation prior to targeted re-sequencing on Next-Gen platforms. As clinical Next-Gen sequencing rapidly expands into the mainstream molecular testing market, the growth of this market segment is expected to be explosive. Some analysts project that the market for targeted clinical sequencing alone will reach $750M by 2015. SmartChip TE addresses CLIA-certified and clinical research laboratories' significant unmet needs in sequencing-based testing by providing superior flexibility, specificity, and sensitivity. The superior performance of this new product is based on WaferGen's proprietary technology that relies on massively parallel singleplex PCR reactions, where amplification is cleaner and better controlled, thereby providing more accurate results in the downstream sequencing step. Each target is amplified in an individual reaction, yielding close to eq
WaferGen Partners with Salk Institute to Establish a Nano-qPCR Core Lab
PR Newswire - Mon Mar 11, 8:10AM CDT
The Salk Institute and WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the formation of a nano-qPCR Core Laboratory under the guidance of Ronald M. Evans, Professor and March of Dimes Chair in Molecular and Developmental Biology at Salk. The lab will utilize WaferGen's SmartChip System as the backbone technology for high-throughput real-time PCR studies. A major focus will be on designing and testing libraries of assays targeting receptors and transcriptional regulators for important functional pathways, thereby interrogating entire regulatory networks in a highly parallel fashion. It is also envisioned that the nano-qPCR Core Lab will be an important resource for the larger Salk community.
WaferGen Bio-systems Announces Highly Successful Initial Customer Testing of Its Previously Unannounced Novel Target Enrichment Technology for Next-Gen Sequencing (NGS)
PR Newswire - Tue Jan 08, 8:00AM CST
WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the successful completion of a proof-of-concept study using its newly-developed proprietary nano-qPCR technology for sample preparation prior to targeted re-sequencing on Next-Gen platforms. The results can be viewed in white paper form at:
